Artelo Biosciences Regains Nasdaq Compliance by Meeting $1.00 Minimum Bid Price Requirement

Artelo Biosciences, a clinical-stage biopharmaceutical company, has regained compliance with the Nasdaq Stock Market’s listing requirements. The announcement follows confirmation from Nasdaq that the company has met the minimum bid price requirement outlined in its listing rules.

According to the notification received by Artelo Biosciences, the company successfully achieved compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive business days. This milestone resolves a prior deficiency notice issued by Nasdaq and ensures that Artelo Biosciences remains listed on the exchange. The company had been working to address this issue within the timeframe provided by Nasdaq’s guidelines.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 7, 2026

Author

GOAI